These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 33617838)

  • 1. Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer.
    Li Y; Song X; Niu J; Ren M; Tang G; Sun Z; Kong F
    Arch Biochem Biophys; 2021 Apr; 701():108818. PubMed ID: 33617838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
    Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
    Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
    Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2.
    He R; Liu H
    Gene; 2020 Jul; 747():144553. PubMed ID: 32165307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
    Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
    Gao BB; Wang SX
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rg3 inhibits gemcitabine-induced lung cancer cell invasiveness through ROS-dependent, NF-κB- and HIF-1α-mediated downregulation of PTX3.
    Ahmmed B; Kampo S; Khan M; Faqeer A; Kumar SP; Yulin L; Liu JW; Yan Q
    J Cell Physiol; 2019 Jul; 234(7):10680-10697. PubMed ID: 30628067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tunicamycin enhances the suppressive effects of cisplatin on lung cancer growth through PTX3 glycosylation via AKT/NF-κB signaling pathway.
    Ahmmed B; Khan MN; Nisar MA; Kampo S; Zheng Q; Li Y; Yan Q
    Int J Oncol; 2019 Feb; 54(2):431-442. PubMed ID: 30483742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer.
    Li Y; He LR; Gao Y; Zhou NN; Liu Y; Zhou XK; Liu JF; Guan XY; Ma NF; Xie D
    Cell Death Dis; 2019 Feb; 10(2):99. PubMed ID: 30718500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
    Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
    Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-25-3p promotes cisplatin resistance in Non-small-cell lung carcinoma (NSCLC) through adjusting PTEN/PI3K/AKT route.
    Sun B; Hu N; Cong D; Chen K; Li J
    Bioengineered; 2021 Dec; 12(1):3219-3228. PubMed ID: 34266345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IOX-101 Reverses Drug Resistance Through Suppression of Akt/mTOR/NF-κB Signaling in Cancer Stem Cell-Like, Sphere-Forming NSCLC Cell.
    Fayi MA; Alamri A; Rajagopalan P
    Oncol Res; 2020 Mar; 28(2):177-189. PubMed ID: 31771696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7.
    Pan X; Chen Y; Shen Y; Tantai J
    Cell Death Dis; 2019 Jun; 10(6):429. PubMed ID: 31160576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
    Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
    Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
    Cai Y; Dong ZY; Wang JY
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hesperetin reverses P‑glycoprotein‑mediated cisplatin resistance in DDP‑resistant human lung cancer cells via modulation of the nuclear factor‑κB signaling pathway.
    Kong W; Ling X; Chen Y; Wu X; Zhao Z; Wang W; Wang S; Lai G; Yu Z
    Int J Mol Med; 2020 Apr; 45(4):1213-1224. PubMed ID: 32124932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depleted aldehyde dehydrogenase 1A1 (ALDH1A1) reverses cisplatin resistance of human lung adenocarcinoma cell A549/DDP.
    Wei Y; Wu S; Xu W; Liang Y; Li Y; Zhao W; Wu J
    Thorac Cancer; 2017 Jan; 8(1):26-32. PubMed ID: 27813328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
    Xiao XH; He SY
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.